Pharmaceutical Executive: March 2025 Interactive Digital Edition
View the Pharmaceutical Executive March 2025 issue in an interactive format.
High Impact
As coverage in Pharmaceutical Executive’s March issue reinforces, AI's connections and permutations are seemingly touching all parts of the industry—and only growing.
Mark Frohlich: A ‘Natural’ Leader
Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.
Emerging Biopharma Launches: Strategizing in Today’s Global Market
A look at the current landscape and how young companies can set the stage for product launch.
The ‘People Factor’: Sourcing, Nurturing, and Retaining Talent
Experts weigh in on today’s life sciences leadership-development priorities critical to long-term success.
AI-Enabled Benchmarking: Transforming Performance Measurement for Pharma Brands
Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.
FDA’s New Accelerated Approval Draft Guidance
What biopharma companies need to know about this evolving regulatory pathway.
The Virtual Reality of Modern Pharma Sales and Marketing
Heather Gervais, CEO of Osso VR, discusses how technological advancements in VR are solving problems for pharmaceutical sales reps.
Beyond the Data: Making HCP Analytics Actually Work for Commercial Teams
Traditional approaches to HCP segmentation are no longer sufficient. The challenge now is to maintain personalization at scale while managing large territories and diverse customer bases.
